Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.

Slides:



Advertisements
Similar presentations
CMRSC Division of Hematology/Oncology
Advertisements

Project Quality Plans Gillian Sandilands Director of Quality
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Essential Documentation GCP Training Seminar 12th October 2011
Tips to a Successful Monitoring Visit
M ODULE F: P RE - STUDY A SSESSMENT V ISIT Denise Thwing 14 Apr Version: Final 14-Apr-2010.
STRATEGIC PLANNING FOR Post-Clearance Audit (PCA)
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Internal verification and external standards moderation.
IAEA International Atomic Energy Agency. IAEA Outline Learning objectives Introduction Functions of Regulatory Body (RB) on EPR Appraisal guidance: Part.
Monitoring and Auditing
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
How to Prepare for a FTCA Site Visit Office Hours
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Managing Sponsorship Research Services University of Oxford.
D. Keane June Internal Quality Audits (4.14) -ISO Requirements for Internal Audits -The Audit Process -Templates for Meeting Requirements.
FPSC Safety, LLC ISO AUDIT.
Laura Cocking Senior Data Manager Peninsula Clinical Trials Unit A Trial Manager’s Guide to Data Management Exeter Clinical Trials Support Network Event.
National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP) A single system for processing and reviewing applications.
Photocopies Occasionally need uncontrolled copies
CPA is a UKAS company The Assessment Process 2014 Seminars.
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
1 of 39 DQO Implementation Process: Flow Chart and Wall Charts 30 minutes DQO Training Course Day 2 Module 8 Presenter: Sebastian Tindall.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Introduction to ISO New and modified requirements.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Audits and Inspections in Clinical Research Jobin Kunjumon Vilapurathu.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Monitoring, Audits, and Inspection Oh my! Rachel Sheppard Regulatory Director, OCRSS.
Verification: Quality Assurance in Assessment Verification is the main quality assurance process associated with assessment systems and practice - whether.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
ISO 9001: 2000 Certified Audit Process What to do.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
1 Thank you for visiting our site and welcome to the “Introduction to ISO 22000” Presentation that you requested. For more information.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Evaluation Plan New Jobs “How to Get New Jobs? Innovative Guidance and Counselling 2 nd Meeting Liverpool | 3 – 4 February L Research Institute Roula.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
College Reviews An Overview Presented by Howard Lutwak, CIA Director of Internal Audit January 2004.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Study Closure Process Entropy is not a method Rachel Sheppard Regulatory Director, OCRSS.
Quality control and audit visit: process & actions.
1 The Future Role of the Food and Veterinary Office M.C. Gaynor, Director, FVO EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate.
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Sponsor Visits and Monitoring
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Training for organisations participating in Peer Review of Paediatric Diabetes.
Surviving CTIMPs and MHRA inspections Kim Gooding Diabetes and Vascular Medicine UEMS and Exeter CRF Exeter Clinical Research Facility.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Briefing on MHRA routine inspection of non-commercial clinical trials
Remote Site Initiation Visits
Responsibilities of Sponsor, Investigator and Monitor
PREPARATION FOR GMP INSPECTION
How to conduct Effective Stage-1 Audit
Discrepancy Management
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi

PROCEDURES 1 - Preparing for the Audit 2 - Conducting the Audit 3 - Reporting the Audit 15 working days Draft Report Issued 15 working days Responses Provided Responses Reviewed/Accepted Final Report Issued

Responsibilities Lead Auditor: Will facilitate organising, conducting and reporting of the audit. He/she will lead the audit activities and will prepare the audit report PSA (Project Specific Auditor) In line with Line Management is responsible for: - Development of the audit programme - Being the focal point of contact with the clinical teams for audits - Ensuring that auditors conducting audits are aware of project related audit issues

Responsibilities (cont’d) Process Owner: He/she is responsible for Harmonisation of all operational activities of the process, including its development and improvement

SYSTEMS AUDITS

What are Global Systems Audits? A systems audit is a review of the organisation, procedures and documentation related to a selected system, or an examination of a process or group of processes that result in an end product.

Why a “systems” approach? Why a “systems” approach ? All work is process driven and the systems approach focuses on auditing the process It can act as key fact finding tool for process improvement It can provide an evaluation of interfaces within Sponsor, and between Sponsor and preferred providers It can assess of cross-functional consistency in a global organisation

Some of the key areas for which a systems approach would be adopted include: Process Management and Training Trial Management Monitoring Data Management Safety Management Investigational Product (IP) Management Archiving of Essential Documents Computerised systems

How are they performed? Systems audits may consist of visit-based audits covering a number of locations or desk-based from the CQA offices. The audits may be conducted as a combination of documentation review, questionnaires and/or Interview

Audit Procedure Preparation Assign Audit Team Identify Audit Sponsor (global/local) Define scope of the audit Define audit references and standards Develop audit plan & tools (e.g. audit method questionnaires, checklists, agenda) Identify audit sample Notification – early enough to ensure that personnel involved are available Request for documentation

Audit Procedure Audit Procedure (cont’d) Conducting the Audit Audit may involve visits to one or more Sponsor sites or may be conducted via telephone discussions and review of documents only Duration – between 2 and 4 days per site Balance between discussions, review of documents and review of facilities Discussions – encouraging staff to explain their daily work, understanding the issue & root cause Focus is not on the individual Review of documents – e.g. procedures, training records, CVs, job descriptions, documents related to the system audited Review of facilities – e.g. archive

Audit Procedure Audit Procedure (cont’d) Reporting and Follow-up Initial feedback at the end of the audit Draft audit report issued to Audit Sponsor for responding Final report includes responses and actions Audit Sponsor responsible for follow-up audit findings

Investigator Site Audits ABC HOSPITAL

Why Investigator Sites? Obligation to ensure that studies are conducted to the relevant national and international laws Obligation to ensure that studies are conducted to GCP Assurance that the company and investigator sites would stand up to a regulatory inspection

Which studies? –regulatory submission status –priority of the project in R&D portfolio –pivotal status of study Which centres? –1 - 15% Investigator Site Audits

Selection of investigator sites is based on: Recruitment Site workload Site with new investigator, monitoring staff or using new systems Coordinating investigator sites Requests from study teams/compliance concerns (“For cause”)

How are they performed? Examination of 3 basic aspects –Nature of the investigator’s conduct of the study –The interaction between the monitor and the investigator –Patient source data that supports entries on the CRF In 2 steps –At monitor’s office –At study site Investigator Site Audits

What happens at the investigator site? OPENING MEETING Introductions Objectives Audit procedure Investigator interview Role of staff INVESTIGATOR FILE AUDIT SOURCE DATA VERIFICATION DRUG STORAGE/DISPENSING ACCOUNTABILITY EXIT MEETING Verbal feedback - key audit observations Clarify any outstanding issues Auditor notes investigator’s comments Thank site staff TOUR OF STUDY RELATED FACILITIES / EQUIPMENT

DOCUMENT AUDITS

Scope of Document Audits The document audits refer but are not limited to: -High Level Documents (HLDs) (integrated summary of data across studies for a particular section of a regulatory submission) -Investigator’s Brochures (IBs) -Clinical Study Protocols (CSPs) -Clinical Study Reports (CSRs) The quality of the document is assessed for internal consistency and against appropriate source documents, further to GCP and applicable regulatory requirements

How are they performed? Review against relevant clinical SOPs, guidelines, templates, etc. Check for completeness and logic A review of the text for accuracy and consistency A review against the source

DATABASE AUDITS

SCOPE It is limited to the information in the clinical study database and the supporting documentation for the process from database set up to clean file The audit of one database is divided into blocks and may be staged over time

PROCEDURE Audit Structure It will be conducted in 3 blocks: 1)To verify presence and approval of a selection of DM documentation for the study 2)To verify data with clean data status from data entry site 3)To verify data that have completed central validation and to verify selected DM documentation

PROCEDURE Electronic Data Capture For studies using Web Based Data Capture the procedure will be adjusted by omitting the verification of clean data from blocks 2 and 3

Audit of Clinical Research Organisations and Clinical Laboratories

This audit covers but is not limited to: Clinical Research Organisations (CROs) Academic Research Organisations Site Management Organisations Collaborative Research Groups Clinical Laboratories (Labs) Other external provides of services such as IVRS, e-clinical technologies, etc. Clinical Pharmacology Units (CPUs)

SCOPE OF THE AUDIT It may be one of 3 types: Initial assessment audit of capabilities before work is transferred to the CRO/Lab Follow-up of assessment of ongoing activities For-cause audit where specific problems have been highlighted